ANIP — ANI Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00HealthcareAdventurousMid CapHigh Flyer
- $697.54m
- $960.68m
- $316.39m
- 74
- 42
- 93
- 80
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 14.4 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.22 | ||
| Price to Tang. Book | 20.62 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.2 | ||
| EV to EBITDA | 44.44 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -5.34% | ||
| Return on Equity | -15.29% | ||
| Operating Margin | -11.15% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 201.58 | 206.55 | 208.47 | 216.14 | 316.38 | 361.63 | 412.32 | 12.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +15.7 | -33.68 | n/a | n/a | n/a | n/a | +60.87 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company that serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceuticals, including for diseases with unmet medical needs. The Company is focused on developing and manufacturing niche oncology products (anti-cancer). It has a commercial portfolio of over 101 products with a variety of indications and a portfolio of pipeline products. The Company owns the facility, which includes oral solid dose and liquid manufacturing and packaging, warehouse facilities, analytical, stability, and microbiological laboratory space, and employee office and mechanical space. It also owns a manufacturing facility that includes oral solid dose manufacturing and packaging for pharmaceutical products. Its four pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, one is located in East Windsor, New Jersey and one is located in Oakville, Ontario.
Directors
- Patrick Walsh CHM (60)
- Nikhil Lalwani PRE (44)
- Stephen Carey CFO (51)
- Chad Gassert SVP
- Ori Gutwerg SVP (47)
- James Marken SVP (58)
- Davinder Singh GMG
- Muthusamy Shanmugam OTH (54)
- Christopher Mutz OTH (50)
- Robert Brown IND (70)
- Thomas Haughey IND (57)
- David Nash IND (65)
- Antonio Pera IND (63)
- Jeanne Thoma IND (61)
- Last Annual
- December 31st, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- April 11th, 2001
- Public Since
- May 4th, 2000
- No. of Shareholders
- 232
- No. of Employees
- 600
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 17,504,088
- Address
- 210 Main Street West, BAUDETTE, 56623
- Web
- https://www.anipharmaceuticals.com/
- Phone
- +1 2186343500
- Contact
- Lisa Wilson
- Auditors
- EisnerAmper LLP
Upcoming Events for ANIP
Q1 2023 ANI Pharmaceuticals Inc Earnings Release
Q2 2023 ANI Pharmaceuticals Inc Earnings Release
Similar to ANIP
ADMA Biologics
NASDAQ Global Market
Alimera Sciences
NASDAQ Global Market
Aptorum
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
What is the ANI Pharmaceuticals share price?
As of Today at 12:01 UTC, shares in ANI Pharmaceuticals are trading at $39.85. This share price information is delayed by 15 minutes.
How has the ANI Pharmaceuticals share price performed this year?
Shares in ANI Pharmaceuticals last closed at $39.85 and the price had moved by +48.03% over the past 365 days. In terms of relative price strength the ANI Pharmaceuticals share price has outperformed the S&P500 Index by +66.85% over the past year.
What are the analyst and broker recommendations for ANI Pharmaceuticals?
The overall consensus recommendation for ANI Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the ANI Pharmaceuticals dividend yield?
ANI Pharmaceuticals does not currently pay a dividend.
Does ANI Pharmaceuticals pay a dividend?
ANI Pharmaceuticals does not currently pay a dividend.
When does ANI Pharmaceuticals next pay dividends?
ANI Pharmaceuticals does not currently pay a dividend.
How do I buy ANI Pharmaceuticals shares?
To buy shares in ANI Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ANI Pharmaceuticals?
As of the previous close price of $39.85, shares in ANI Pharmaceuticals had a market capitalisation of $697.54m.
Where are ANI Pharmaceuticals shares listed?
Here are the trading details for ANI Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ANIP
What kind of share is ANI Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum ANI Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ANI Pharmaceuticals share price forecast for 2023?
The analyst consensus target price for shares in ANI Pharmaceuticals is $49.20. That is 23.46% above the last closing price of $39.85.
Analysts covering ANI Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $2.44 for the next financial year.
What is the trend in the ANI Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ANI Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +10.48%.
As of the last closing price of $39.85, shares in ANI Pharmaceuticals were trading +8.08% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ANI Pharmaceuticals PE Ratio?
The ANI Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 14.4. The shares last closed at $39.85.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ANI Pharmaceuticals?
ANI Pharmaceuticals' management team is headed by:
- Patrick Walsh - CHM
- Nikhil Lalwani - PRE
- Stephen Carey - CFO
- Chad Gassert - SVP
- Ori Gutwerg - SVP
- James Marken - SVP
- Davinder Singh - GMG
- Muthusamy Shanmugam - OTH
- Christopher Mutz - OTH
- Robert Brown - IND
- Thomas Haughey - IND
- David Nash - IND
- Antonio Pera - IND
- Jeanne Thoma - IND